MAbs largest class of biotherapeutics

8 December 2011

Monoclonal antibodies (MAbs) were the fastest growing segment in the global pharmaceutical market in 2010, when the global MAb market was worth $43 billion while the rest of the biologics market was approximately $108 billion, according to a new report from GBI Research.

Application of MAbs ranges from various oncology indications to autoimmune diseases. Gradually, MAbs are beginning to pave their way into the treatment of central nervous system (CNS) disorders such as Alzheimer’s disease and metabolic disorders such as diabetes. The first Food and Drug Administration-approved therapeutic monoclonal antibody was a murine IgG2a CD3 specific transplant rejection drug, OKT3 (also called muromonab) in 1986. This drug found use in solid organ transplant recipients who became steroid resistant

MAb successes

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Biotechnology